Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genasense in Merkel Cell Carcinoma
NCT00079131Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2004
- Primary completion
- Jan 2007
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of oblimersen in Merkel cell carcinoma (MCC), sponsored by National Cancer Institute. Started Jan 2004; status: completed.
02
Drugs
oblimersen
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT00079131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00079131.